AI Article Synopsis
- * A rare but serious complication called late-onset neutropenia (LON) was observed in a patient three months after the last dose of ocrelizumab, necessitating treatment with antibiotics and filgrastim.
- * This case emphasizes the need for regular blood tests to monitor for severe neutropenia, which can occur unexpectedly and poses significant health risks.
Article Abstract
Ocrelizumab is a recombinant humanized antibody targeted against CD-20 molecule, which was approved for the treatment of relapsing and primary progressive multiple sclerosis. Common adverse events of ocrelizumab include infusion-related reactions like rash, pruritus, and flushing. Late-onset neutropenia (LON) is a rarely reported complication of ocrelizumab therapy. We report a case of severe late-onset neutropenia in a patient with primary progressive multiple sclerosis treated with ocrelizumab with neutropenia occurring 3 months after the last dose received treated with empirical broad-spectrum intravenous antibiotics and filgrastim. Severe late-onset neutropenia is a rare unpredictable adverse event and outlines the importance of regular routine blood workup for detecting severe neutropenia early in its course.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770231 | PMC |
| http://dx.doi.org/10.1002/ccr3.5299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neonatal Late-Onset Sepsis Due to Acinetobacter baumannii: A Case Report.
Cureus
November 2024
Neonatology Department, Maternidade Daniel de Matos, Unidade Local de Saúde de Coimbra, Coimbra, PRT.
Late-onset sepsis (LOS) is commonly associated with pathogens acquired in hospital or community settings and carries a significant risk of morbidity and mortality in neonates. We present a case of a late preterm neonate, born at 36 weeks and 2 days with low birth weight (1700 g), who was admitted to the neonatal intensive care unit (NICU) and developed LOS on the fourth day of life. LOS was diagnosed in the context of fever and lethargy, mild thrombocytopenia, leukopenia, and lymphopenia, and was caused by multidrug-resistant (MDR) , confirmed through blood culture.
View Article and Find Full Text PDFProlonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis in a patient with acute lymphoblastic leukemia.
Blood Cell Ther
November 2024
Department of Pediatrics, Tokai University School of Medicine, Kanagawa, Japan.
Immune effector cell-associated neurotoxicity syndrome usually occurs within the first four weeks of chimeric antigen receptor (CAR)-T cell therapy. In addition, prolonged cytopenia is a long-term adverse effect following the use of CAR T-cell therapies. Here, we present a case of prolonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis.
View Article and Find Full Text PDFA rare case of late-onset spondyloenchondrodysplasia with immune dysregulation presenting as adult-onset monogenic lupus.
Lupus
January 2025
Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Background: Spondyloenchondrodysplasia is classified as an interferonopathy resulting from recessive mutations in the gene and manifests with various clinical features, including distinctive skeletal dysplasia, neurological abnormalities, immune dysfunction resembling systemic lupus erythematosus (SLE) and Sjogren's syndrome. While SLE is typically considered multifactorial and more prevalent in adulthood, a subset of approximately 10%-25% of childhood cases arise from monogenic form. Among these, spondyloenchondrodysplasia accounts for only a rare fraction of monogenic lupus cases, with only 22 reported instances in the literature.
View Article and Find Full Text PDFRecurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis.
Med
October 2024
Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany. Electronic address:
Background: As B cell-depleting therapies in multiple sclerosis (MS) have gained significant importance in the last several years, their long-term safety profile is of considerable clinical interest. Late-onset neutropenia (LON) is a rare, but potentially severe, adverse event that was first described in patients with rheumatic disorders under therapy with rituximab. Ofatumumab was approved in 2021 for the treatment of relapsing-remitting multiple sclerosis (RRMS).
View Article and Find Full Text PDFBlood-dominant disease in late-and-early-onset lupus: A systematic review and meta-analysis.
Autoimmun Rev
November 2024
Division of Rheumatology, University Hospitals/Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH, 44106, USA.. Electronic address:
Article Synopsis
- - This study aims to compare the hematological manifestations between early-onset systemic lupus erythematosus (erSLE) patients (aged ≤50) and late-onset patients (ltSLE) (aged >50) through a meta-analysis of previous research.
- - Results from 39 studies involving over 19,000 patients show that erSLE patients exhibit higher frequencies of autoimmune hemolytic anemia, lymphopenia, leukopenia, and lymphadenopathy compared to ltSLE patients, while the rates of thrombosis and thrombocytopenia were similar in both groups.
- - The findings suggest that it may be challenging to link certain hematological issues to SLE in older patients due to other
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!